Human papillomavirus vaccine and men: What are the obstacles and challenges?

Current Opinion in Infectious Diseases

Volumn 25, Issue 1, 2012, Pages 86-91

  Stupiansky, Nathan W ^a   Alexander, Andreia B ^a   Zimet, Gregory D ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Human papillomavirus; Men; Vaccine

Indexed keywords

WART VIRUS VACCINE;

AWARENESS; BISEXUAL MALE; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; HEALTH EDUCATION; HEALTH PERSONNEL ATTITUDE; HEALTH PROGRAM; HEALTH SURVEY; HETEROSEXUAL MALE; HIGH RISK POPULATION; HUMAN; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INFECTION SENSITIVITY; MALE HOMOSEXUAL; MALE VACCINATION; PARENTAL ATTITUDE; PATIENT ATTITUDE; PENIS CANCER; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SEXUALLY TRANSMITTED DISEASE; VACCINATION; VIRUS INFECTION; WART VIRUS;

ATTITUDE OF HEALTH PERSONNEL; COST-BENEFIT ANALYSIS; HUMANS; MALE; MASS VACCINATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; UNITED STATES;

EID: 84155163104     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834ed5be     Document Type: Review

References (46)

1. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011; 364:401-411.
2. Giuliano AR, Anic G, Nyitray AG. Epidemiology and pathology of HPV disease in males. Gynecol Oncol 2010; 117:S15-S19.
3. U.S. Food and Drug Administration. Package Insert - Gardasil. http:// www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/Approved- Products/UCM111263.pdf. 2010. [Accessed 13 September 2011]
4. Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010; 59:630-632.
5. Merck Sharp & Dohme Corp. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine. http://www.medsafe.govt.nz/Profs/Datasheet/g/ Gardasilinj.pdf. 2010. [Accessed 17 September 2011]
6. MIMS Australia. Gardasil: MIMS abbreviated prescribing information. http:// avn.org.au/nocompulsoryvaccination/wp-content/uploads/2011/02/Gardasil. pdf 0.2010. [Accessed 17 September 2011]
7. Zimet GD, Rosenthal SL. HPV vaccine and males: issues and challenges. Gynecol Oncol 2010; 117:S26-S31.
8. Liddon N, Hood J, Wynn BA, Markowitz LE. Acceptability of human papillomavirus vaccine for males: a review of the literature. J Adolesc Health 2010; 46:113-123.
9. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among adolescents aged 13-17 years - United States, 2009. MMWR 2010; 59:1018-1023.
10. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13 through 17 years - United States, 2010. MMWR 2011; 60:1117-1123.
11. Reiter PL, McRee A-L, Kadis JA, Brewer NT. HPV vaccine and adolescent males. Vaccine 2011; 29:5595-5602.
12. Marcell AV, Klein JD, Fischer I, et al. Male adolescent use of healthcare services: where are the boys? J Adolesc Health 2002; 30:35-43.
13. National Adolescent Health Information Center. A health profile of adolescent and young adult males. San Francisco: University of California, San Francisco; 2005.
14. Reiter PL, McRee A-L, Gottlieb SL, Brewer NT. HPV vaccine for adolescent males: acceptability to parents postvaccine licensure. Vaccine 2010; 28: 6292-6297.
15. Gilbert P, Brewer NT, Reiter PL, et al. HPV vaccine acceptability in heterosexual, gay, and bisexual men. Am J Mens Health 2011; 5:297-305.
16. Gilbert PA, Brewer NT, Reiter PL. Association of human papillomavirusrelated knowledge, attitudes, and beliefs with HIV status: a national study of gay men. J Low Genit Tract Dis 2011; 15:83-88.
17. Thomas EA, Goldstone SE. Should I or shouldn't I: decision making, knowledge and behavioral effects of quadrivalent HPV vaccination in men who have sex with men. Vaccine 2011; 29:570-576.
18. Wheldon CW, Daley EM, Buhi ER, et al. Health beliefs and attitudes associated with HPV vaccine intention among young gay and bisexual men in the southeastern United States. Vaccine 2011; 29:8060-8065.
19. Daley EM, Marhefka SL, Buhi ER, et al. Human papillomavirus vaccine intentions among men participating in a human papillomavirus natural history study versus a comparison sample. Sex Transm Dis 2010; 37:644-652.
20. Daley EM, Marhefka S, Buhi E, et al. Ethnic and racial differences in HPV knowledge and vaccine intentions among men receiving HPV test results. Vaccine 2011; 29:4013-4018.
21. Pitts M, Smith A, Croy S, et al. Singaporean men's knowledge of cervical cancer and human papillomavirus (HPV) and their attitudes towards HPV vaccination. Vaccine 2009; 27:2989-2993.
22. Oh J-K, Lim MK, Yun EH, et al. Awareness of and attitude towards human papillomavirus infection and vaccination for cervical cancer prevention among adult males and females in Korea: a nationwide interview survey. Vaccine 2010; 28:1854-1860.
23. Wong LP. Role of men in promoting the uptake of HPV vaccinations: focus groups' finding from a developing country. Int J Public Health 2010; 55:35-42.
24. McRee A-L, Reiter PL, Chantala K, Brewer NT. Does framing human papillomavirus vaccine as preventing cancer in men increase vaccine acceptability? Cancer Epidemiol Biomarkers Prev 2010; 19:1937-1944.
25. Gerend MA, Barley J. Human papillomavirus vaccine acceptability among young adult men. Sex Transm Dis 2009; 36:58-62.
26. DiClemente RJ, Crosby RA, Salazar LF, et al. Is male intent to be vaccinated against HPV a function of the promotion message? Int J STD AIDS 2011; 22:332-334.
27. Gerend MA, Sias T. Message framing and color priming: how subtle threat cues affect persuasion. J Exp Soc Psychol 2009; 45:999-1002.
28. Rosenthal SL, Weiss TW, Zimet GD, et al. Predictors of HPV vaccine uptake among women ages 19-26: importance of a physician's recommendation. Vaccine 2011; 29:890-895.
29. Gerend MA, Weibley E, Bland H. Parental response to human papillomavirus vaccine availability: uptake and intentions. J Adolesc Health 2009; 45:528-531.
30. Yeganeh N, Curtis D, Kuo A. Factors influencing HPV vaccination status in a Latino population; and parental attitudes towards vaccine mandates. Vaccine 2010; 28:4186-4191.
31. Fernandez ME, Allen JD, Mistry R, Kahn JA. Integrating clinical, community, and policy perspectives on human papillomavirus vaccination. Ann Rev Public Health 2010; 31:235-252.
32. Weiss TW, Zimet GD, Rosenthal SL, et al. Human papillomavirus vaccination of males: attitudes and perceptions of physicians who vaccinate females. J Adolesc Health 2010; 47:3-11.
33. Dempsey AF, Butchart A, Singer D, et al. Factors associated with parental intentions for male human papillomavirus vaccination: results of a national survey. Sex Transm Dis 2011; 38:769-776.
34. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010; 28:6858-6867.
35. Chesson HW, Ekwueme DU, Saraiya M, et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011; 29:8443-8450.
36. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. Br Med J 2008; 337:a769.
37. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010; 10:845-852.
38. Insinga RP, Dasbach EJ, Elbasha EH, et al. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007; 26:128-139.
39. Zechmeister I, de Blasio BF, Garnett G, et al. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 2009; 27:5133-5141.
40. Brisson M, Van de Velde N, Franco EL, et al. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 2011; 204:372-376.
41. Smith MA, Lew J-B, Walker RJ, et al. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine 2011; 29:9112-9122.
42. Johnson FR. Moving the QALY forward or just stuck in traffic. Value Health 2009; 12:S38-S39.
43. Nord E, Daniels N, Kamlet M. QALYs: some challenges. Value Health 2009; 12:S10-S15.
44. Giuliano AR, Salmon D. The case for a gender-neutral (universal) human papillomavirus vaccination policy in the United States: Point. Cancer Epidemiol Biomarkers Prev 2008; 17:805-808.
45. Michels KB, zur Hausen H. HPV vaccine for all. Lancet 2009; 374:268-270.
46. Szarewski A. HPV vaccines: peering through the fog. J Fam Plann Reprod Healthcare 2008; 34:207-209.